Treatment of Chronic Myeloid Leukemia Elderly Patients in the Tyrosine Kinase Inhibitor Era

By  

Current Cancer Drug Targets, Vol. 13, Iss. 7, 2013-09 ,pp. : 755-767

Bentham Science Publishers

Access to resources Recommend Favorite

New Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia

By  

Current Pharmaceutical Biotechnology, Vol. 7, Iss. 5, 2006-10 ,pp. : 371-379

Bentham Science Publishers

Access to resources Recommend Favorite

Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr–Abl mutations and mutational analysis

By Soverini Simona   Martinelli Giovanni   Rosti Gianantonio   Iacobucci Ilaria   Baccarani Michele  

Pharmacogenomics, Vol. 13, Iss. 11, 2012-08 ,pp. : 1271-1284

Future Medicine

Access to resources Recommend Favorite

Second-Generation Tyrosine Kinase Inhibitors as First-Line Treatment Strategy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients

By  

Current Cancer Drug Targets, Vol. 12, Iss. 4, 2012-04 ,pp. : 391-401

Bentham Science Publishers

Access to resources Recommend Favorite

Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3–tyrosine kinase domain mutations

By Alvarado Yesid   Kantarjian Hagop M.   Luthra Rajyalakshmi   Ravandi Farhad   Borthakur Gautam   Garcia-Manero Guillermo   Konopleva Marina   Estrov Zeev   Andreeff Michael   Cortes Jorge E.  

Cancer, Vol. 120, Iss. 14, 2014-07 ,pp. : 2142-2149

Blackwell Publishing

Access to resources Recommend Favorite